RT Journal Article
SR Electronic
T1 Limited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 116
OP 119
DO 10.3899/jrheum.080664
VO 36
IS 1
A1 CURRY L. KOENING
A1 JOSÉ HERNÁNDEZ-RODRÍGUEZ
A1 EAMONN S. MOLLOY
A1 TIFFANY M. CLARK
A1 GARY S. HOFFMAN
YR 2009
UL http://www.jrheum.org/content/36/1/116.abstract
AB Objective We report our experience using rapamycin in patients with Wegener’s granulomatosis (WG) who failed to achieve remission with conventional treatment. Methods Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively. Results Four patients treated with rapamycin sustained remissions of at least 6 months’ duration while receiving prednisone ≤ 10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events. Conclusion Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.